Aclaris Therapeutics, Inc. splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was License And Service at $1.2 million, 80% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6
|
1
|
2
|
2
|
1
|
3
|
2
|
1
|
9
|
| License And Service |
5
-65.8%
share 73.6%
|
1
-58.0%
share 79.7%
|
1
-4.6%
share 78.1%
|
1
+44.5%
share 73.1%
|
1
-90.8%
share 61.4%
|
3
share 85.3%
|
1
share 75.1%
|
1
share 69.4%
|
9
share 93.3%
|
| Laboratory Research Revenue |
2
-14.8%
share 26.4%
|
0
-38.1%
share 20.3%
|
0
-19.5%
share 21.9%
|
1
+20.7%
share 26.9%
|
0
-18.7%
share 38.6%
|
0
share 14.7%
|
0
share 24.9%
|
0
share 30.6%
|
1
share 6.7%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACRS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wayne, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1557746
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.